Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $55.00.

Several equities analysts have recently commented on PTHS shares. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Piper Sandler started coverage on Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 price objective on the stock. Oppenheimer increased their price objective on Pelthos Therapeutics from $60.00 to $62.00 and gave the company an “outperform” rating in a research report on Friday, March 20th. Finally, Roth Mkm reduced their price objective on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th.

Hedge Funds Weigh In On Pelthos Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Ikarian Capital LLC grew its position in Pelthos Therapeutics by 309.5% during the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after acquiring an additional 193,307 shares during the last quarter. Millennium Management LLC bought a new position in Pelthos Therapeutics during the 4th quarter worth approximately $343,000. Boothbay Fund Management LLC grew its position in Pelthos Therapeutics by 279.8% during the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after acquiring an additional 59,435 shares during the last quarter. J. Goldman & Co LP bought a new position in Pelthos Therapeutics during the 4th quarter worth approximately $2,418,000. Finally, Cantor Fitzgerald L. P. bought a new position in Pelthos Therapeutics during the 4th quarter worth approximately $1,085,000. 77.96% of the stock is currently owned by institutional investors.

Pelthos Therapeutics Trading Down 6.7%

Shares of Pelthos Therapeutics stock opened at $22.74 on Wednesday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.05 and a quick ratio of 1.15. The company has a market cap of $76.41 million, a price-to-earnings ratio of -1.10 and a beta of 3.93. The firm’s 50-day moving average price is $22.80. Pelthos Therapeutics has a 12 month low of $9.00 and a 12 month high of $54.29.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).